Glucose Transporter Type 4

"Glucose Transporter Type 4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A glucose transport protein found in mature MUSCLE CELLS and ADIPOCYTES. It promotes transport of glucose from the BLOOD into target TISSUES. The inactive form of the protein is localized in CYTOPLASMIC VESICLES. In response to INSULIN, it is translocated to the PLASMA MEMBRANE where it facilitates glucose uptake.

Descriptor ID	D051275
MeSH Number(s)	D12.776.157.530.500.500.937 D12.776.157.530.937.563.937 D12.776.543.585.500.500.937 D12.776.543.585.937.625.937
Concept/Terms	Glucose Transporter Type 4 Glucose Transporter Type 4 Insulin-Responsive Glucose Transporter Glucose Transporter, Insulin-Responsive Insulin Responsive Glucose Transporter SLC2A4 Protein Solute Carrier Family 2, Facilitated Glucose Transporter, Member 4 Protein GLUT4 Protein GLUT-4 Protein GLUT 4 Protein

Below are MeSH descriptors whose meaning is more general than "Glucose Transporter Type 4".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Carrier Proteins [D12.776.157]
Membrane Transport Proteins [D12.776.157.530]
Monosaccharide Transport Proteins [D12.776.157.530.500]
Glucose Transport Proteins, Facilitative [D12.776.157.530.500.500]
Glucose Transporter Type 4 [D12.776.157.530.500.500.937]
Solute Carrier Proteins [D12.776.157.530.937]
Glucose Transport Proteins, Facilitative [D12.776.157.530.937.563]
Glucose Transporter Type 4 [D12.776.157.530.937.563.937]
Membrane Proteins [D12.776.543]
Membrane Transport Proteins [D12.776.543.585]
Monosaccharide Transport Proteins [D12.776.543.585.500]
Glucose Transport Proteins, Facilitative [D12.776.543.585.500.500]
Glucose Transporter Type 4 [D12.776.543.585.500.500.937]
Solute Carrier Proteins [D12.776.543.585.937]
Glucose Transport Proteins, Facilitative [D12.776.543.585.937.625]
Glucose Transporter Type 4 [D12.776.543.585.937.625.937]

Below are MeSH descriptors whose meaning is related to "Glucose Transporter Type 4".

Below are MeSH descriptors whose meaning is more specific than "Glucose Transporter Type 4".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Glucose Transporter Type 4" by people in this website by year, and whether "Glucose Transporter Type 4" was a major or minor topic of these publications.

Bar chart showing 12 publications over 9 distinct years, with a maximum of 2 publications in 2009 and 2018 and 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2004	0	1	1
2005	0	1	1
2009	0	2	2
2015	0	1	1
2018	1	1	2
2019	2	0	2
2020	1	0	1
2021	0	1	1
2023	0	1	1

Below are the most recent publications written about "Glucose Transporter Type 4" by people in Profiles.

Bajpeyi S, Apaflo JN, Rosas V, Sepulveda-Rivera K, Varela-Ramirez A, Covington JD, Galgani JE, Ravussin E. Effect of an acute long-duration exercise bout on skeletal muscle lipid droplet morphology, GLUT 4 protein, and perilipin protein expression. Eur J Appl Physiol. 2023 Dec; 123(12):2771-2778.

View in: PubMed
Fujimoto BA, Young M, Nakamura N, Ha H, Carter L, Pitts MW, Torres D, Noh HL, Suk S, Kim JK, Polgar N. Disrupted glucose homeostasis and skeletal-muscle-specific glucose uptake in an exocyst knockout mouse model. J Biol Chem. 2021 Jan-Jun; 296:100482.

View in: PubMed
Tilekar K, Upadhyay N, Hess JD, Macias LH, Mrowka P, Aguilera RJ, Meyer-Almes FJ, Iancu CV, Choe JY, Ramaa CS. Structure guided design and synthesis of furyl thiazolidinedione derivatives as inhibitors of GLUT 1 and GLUT 4, and evaluation of their anti-leukemic potential. Eur J Med Chem. 2020 Sep 15; 202:112603.

View in: PubMed
Fujimoto BA, Young M, Carter L, Pang APS, Corley MJ, Fogelgren B, Polgar N. The exocyst complex regulates insulin-stimulated glucose uptake of skeletal muscle cells. Am J Physiol Endocrinol Metab. 2019 12 01; 317(6):E957-E972.

View in: PubMed
Oyinloye BE, Adekiya TA, Aruleba RT, Ojo OA, Ajiboye BO. Structure-Based Docking Studies of GLUT4 Towards Exploring Selected Phytochemicals from Solanum xanthocarpum as a Therapeutic Target for the Treatment of Cancer. Curr Drug Discov Technol. 2019; 16(4):406-416.

View in: PubMed
Diep DTV, Hong K, Khun T, Zheng M, Ul-Haq A, Jun HS, Kim YB, Chun KH. Anti-adipogenic effects of KD025 (SLx-2119), a ROCK2-specific inhibitor, in 3T3-L1 cells. Sci Rep. 2018 02 06; 8(1):2477.

View in: PubMed
Aruleba RT, Adekiya TA, Oyinloye BE, Kappo AP. Structural Studies of Predicted Ligand Binding Sites and Molecular Docking Analysis of Slc2a4 as a Therapeutic Target for the Treatment of Cancer. Int J Mol Sci. 2018 Jan 28; 19(2).

View in: PubMed
Darrow AL, Shohet RV. Galectin-3 deficiency exacerbates hyperglycemia and the endothelial response to diabetes. Cardiovasc Diabetol. 2015 Jun 06; 14:73.

View in: PubMed
Cook SA, Varela-Carver A, Mongillo M, Kleinert C, Khan MT, Leccisotti L, Strickland N, Matsui T, Das S, Rosenzweig A, Punjabi P, Camici PG. Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction. Eur Heart J. 2010 Jan; 31(1):100-11.

View in: PubMed
Espinoza-Derout J, Wagner M, Salciccioli L, Lazar JM, Bhaduri S, Mascareno E, Chaqour B, Siddiqui MA. Positive transcription elongation factor b activity in compensatory myocardial hypertrophy is regulated by cardiac lineage protein-1. Circ Res. 2009 Jun 19; 104(12):1347-54.

View in: PubMed

People

Explore

Similar Concepts

Top Journals